[1]
Malaguarnera G, Gagliano C, Giordano M, et al. Homocysteine serum levels in diabetic patients with non proliferative, proliferative and without retinopathy. BioMed Res Int 2014; 2014: 191497.
[2]
Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332(5): 286-91.
[3]
Finkelstein JD. The metabolism of homocysteine: pathways and regulation. Eur J Pediatr 1998; 157(Suppl. 2): S40-4.
[4]
Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999; 19: 217-46.
[5]
Bruix J, Reig M, Rimola J, et al. Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology 2011; 54(6): 2238-44.
[6]
Chan SL, Chong CC, Chan AW, Poon DM, Chok KS. Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. World J Gastroenterol 2016; 22(32): 7289-300.
[7]
Joseph J, Handy DE, Loscalzo J. Quo vadis: whither homocysteine research? Cardiovasc Toxicol 2009; 9(2): 53-63.
[8]
Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 2007; 447(7143): 433-40.
[9]
Wang H, Yoshizumi M, Lai K, et al. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997; 272(40): 25380-5.
[10]
Bosy-Westphal A, Petersen S, Hinrichsen H, Czech NJ, Müller M. Increased plasma homocysteine in liver cirrhosis. Hepatol Res 2001; 20(1): 28-38.
[11]
Undas A, Williams EB, Butenas S, Orfeo T, Mann KG. Homocysteine inhibits inactivation of factor Va by activated protein C. J Biol Chem 2001; 276(6): 4389-97.
[12]
den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998; 80(6): 874-7.
[13]
den Heijer M, Brouwer IA, Bos GM, et al. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol 1998; 18(3): 356-61.
[14]
Malaguarnera G, Catania VE, Francaviglia A, et al. Lipoprotein(a) in patients with hepatocellular carcinoma and portal vein thrombosis. Aging Clin Exp Res 2017; 29(Suppl. 1): 185-90.
[15]
Uccello M, Malaguarnera G, Pelligra EM, Biondi A, Basile F, Motta M. Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma. Indian J Med Paediatr Oncol 2011; 32(2): 71-5.
[16]
Bertino G, Malaguarnera G, Frazzetto E, et al. Responsibility of hepatitis C virus in the development of hepatocellular carcinoma: From molecular alterations to possible solutions. World J Hepatol 2018; 10(6): 448-51.
[17]
Gatt A, Makris M. Hyperhomocysteinemia and venous thrombosis. Semin Hematol 2007; 44(2): 70-6.
[18]
Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990; 21(4): 572-6.
[19]
Vecchio M, Gracies JM, Panza F, et al. Change in Coefficient of Fatigability Following Rapid, Repetitive Movement Training in Post-Stroke Spastic Paresis: A Prospective Open-Label Observational Study. J Stroke Cerebrovasc Dis 2017; 26(11): 2536-40.
[20]
Mangia A, Villani MR, Cappucci G, et al. Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. Eur J Gastroenterol Hepatol 2005; 17(7): 745-51.
[21]
Gayowski TJ, Marino IR, Doyle HR, et al. A high incidence of native portal vein thrombosis in veterans undergoing liver transplantation. J Surg Res 1996; 60(2): 333-8.
[22]
Malaguarnera M, Latteri S, Bertino G, et al. D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosis. Clin Exp Gastroenterol 1996; 11: 373-80.
[23]
Malaguarnera M, Catania VE, Borzì AM, et al. Blood homocysteine levels are increased in hepatocellular carcinoma patients with portal vein thrombosis. A single centre retrospective cohort study. International Journal of Surgery Open 2018; 15: 60-5.
[24]
Brattström LE, Israelsson B, Jeppsson JO, Hultberg BL. Folic acid--an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988; 48(3): 215-21.
[25]
Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4(2): 439-74.
[26]
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28(3): 751-5.
[27]
Daniele B, Annunziata M, Barletta E, Tinessa V, Di Maio M. Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma. Hepatol Res 2007; 37(Suppl. 2): S206-9.
[28]
Malaguarnera G, Bertino G, Vacante M, Malaguarnera M. Hepatocellular carcinoma markers in the omics era: the glycomic analysis. Hepatobiliary Surg Nutr 2014; 3(6)(Suppl. 2): 407-9.
[29]
Lynch SM, Campione AL, Moore MK. Plasma thiols inhibit hemin-dependent oxidation of human low-density lipoprotein. Biochim Biophys Acta 2000; 1485(1): 11-22.
[30]
Bosy-Westphal A, Ruschmeyer M, Czech N, et al. Determinants of hyperhomocysteinemia in patients with chronic liver disease and after orthotopic liver transplantation. Am J Clin Nutr 2003; 77(5): 1269-77.
[31]
Córdoba-Porras A, Sánchez-Quesada JL, González-Sastre F, Ordóñez-Llanos J, Blanco-Vaca F. Susceptibility of plasma low- and high-density lipoproteins to oxidation in patients with severe hyperhomocysteinemia. J Mol Med (Berl) 1996; 74(12): 771-6.
[32]
Werstuck GH, Lentz SR, Dayal S, et al. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 2001; 107(10): 1263-73.
[33]
Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet 2000; 9(16): 2395-402.
[34]
Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 2006; 31(2): 89-97.
[35]
Rapisarda V, Loreto C, Malaguarnera M, et al. Hepatocellular carcinoma and the risk of occupational exposure. World J Hepatol 2016; 8(13): 573-90.
[36]
Latteri S, Malaguarnera G, Mannino M, et al. Ultrasound as point of care in management of polytrauma and its complication. J Ultrasound 2017; 20(2): 171-7.
[37]
Latteri S, Catania VE, Malaguarnera G, et al. Carcinoembryonic Antigen Serum Levels in Nonmelanoma Skin Cancer. Biomedicines 2018; 6(1): 24.
[38]
Gauthier GM, Keevil JG, McBride PE. The association of homocysteine and coronary artery disease. Clin Cardiol 2003; 26(12): 563-8.
[39]
Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270(22): 2693-8.
[40]
Saibeni S, Cattaneo M, Vecchi M, et al. Low vitamin B(6) plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants. Am J Gastroenterol 2003; 98(1): 112-7.
[41]
McCarty MF. Increased homocyst(e)ine associated with smoking, chronic inflammation, and aging may reflect acute-phase induction of pyridoxal phosphatase activity. Med Hypotheses 2000; 55(4): 289-93.
[42]
Uccello M, Malaguarnera G, Corriere T, Biondi A, Basile F, Malaguarnera M. Risk of hepatocellular carcinoma in workers exposed to chemicals Hepat Mon . 2012; 12(10 HCC): e5943.
[43]
Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338(15): 1042-50.
62
3
1
